BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CoStim Pharmaceutical Buyout Bolsters Novartis AG (NVS)'s Cancer Portfolio


2/17/2014 6:21:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CoStim Pharmaceuticals, Inc. Acquired by Novartis

BOSTON
, Feb. 17, 2014 /PRNewswire/ -- MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. ("CoStim") has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

"I am thrilled that we were able to bring together compelling science with a world class team to build the premier biotech company developing a focused and highly attractive pipeline of antibody agents directed to costimulatory targets for the treatment of cancer," said Robert Millman, co-founder of CoStim. "Clearly Novartis shares our vision to become leaders in the treatment of cancer with a pipeline of immune-oncology agents."

The commitment by MPM to build CoStim arose from the 2010 MPM Medical and Scientific Advisory meeting where Professor Arlene Sharpe of Harvard presented her work describing how T cells respond to the complex array of positive and negative inputs from their environment and how blocking negative signals could be even more important for anti-cancer T cell activity than further activating T cells. Working with scientific co-founders Professors Arlene Sharpe, Gordon Freeman and Vijay Kuchroo, CoStim subsequently assembled a portfolio of agents directed at multiple T cell regulatory targets via relationships established with the Dana Farber Cancer Institute, Harvard Medical School, Boston Children's Hospital, Brigham and Women's Hospital, and Immutep SA.

MPM provided the initial capital to found CoStim, and later co-led the formal Series A investment in early 2013 with Atlas Venture. Additional investors included Johnson & Johnson Development Corporation and the Partners Innovation Fund. Robert Millman was initially President of CoStim; Luke Evnin became Chairman of the Board. Dr. Dan Hicklin was subsequently hired as CSO and President.

"The field of immunomodulation is the most exciting area of oncology drug development today," said Dr. Daniel Hicklin, CoStim's President and Chief Scientific Officer. "We are excited about the potential of CoStim's portfolio of immunotherapies and pleased to be joining Novartis to further advance these molecules. We appreciate Novartis' strong commitment and capabilities in oncology which provides an excellent opportunity towards accelerating the development of our therapeutics as new medicines for cancer patients."

About MPM Capital

MPM Capital is one of the world's largest life science-dedicated venture investors. With committed capital under management in excess of $2.6 billion, MPM Capital is uniquely structured to invest globally in powering breakthroughs in life sciences.

About Atlas Venture

Atlas Venture is an early-stage venture capital firm that invests in technology and life sciences companies. Since inception in 1980, its partners have helped build over 400 companies in more than 16 countries. Atlas Venture is currently investing from its ninth fund and manages more than $2 billion in capital. For more information, please visit www.atlasventure.com.

About Partners Innovation Fund

The Partners Innovation Fund is the strategic venture fund for Partners HealthCare, founded by the Massachusetts General Hospital and Brigham and Women's Hospital. The mission of the fund is to provide the necessary support to commercialize innovations in medical informatics, diagnostics, drugs and devices that emerge from the Partners HealthCare investigator community.

SOURCE MPM Capital



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES